KyDo Therapeutics GmbH is a preclinical-stage biotechnology company focused on developing novel covalent-allosteric small molecule inhibitors for oncology
KyDo Therapeutics GmbH is a preclinical-stage biotechnology company focused on developing novel covalent-allosteric small molecule inhibitors for oncology. The company aims to redefine cancer treatment through precision medicine, targeting key cancer drivers to enhance efficacy and minimize side effects.